BPC-157's Human Evidence Gap: What the Research Actually Shows
Zero human clinical trials, one small safety pilot, and 35 rat studies: what "100+ studies on BPC-157" really means before you trust the claim.
BPC-157 has zero peer-reviewed human clinical trials. That single fact gets lost in a lot of the online discussion, so it is worth spelling out exactly what the evidence base actually looks like.
The "100+ Studies" Claim
The number that circulates most often is "100+ studies." That is technically accurate, but almost all of those studies are preclinical, meaning they were conducted in rats, rabbits, or in-vitro tissue samples rather than in people.
A 2025 systematic review examined 36 published studies spanning from 1993 to 2024. Of those 36, exactly one was a clinical study. The other 35 were preclinical.
The entirety of the published human data amounts to a small IRB-approved intravenous safety pilot, showing tolerability at doses up to 20mg with no serious adverse events reported. That is the complete human safety record as it currently stands.
Well-Studied Isn't the Same as Proven
None of this makes the animal data meaningless. Three decades of preclinical tissue-repair research is a genuine signal, not nothing. But "well-studied" and "proven in humans" are two different claims, and BPC-157 currently only earns the first one.
This distinction matters more than usual right now, given that BPC-157 was in front of the FDA's compounding advisory committee this year, and the evidence gap described above is exactly what FDA scientists have flagged in their own review.